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CLINICAL RESEARCH ARTICLE OPEN
Elevated serum IL-10 is associated with severity of neonatal
encephalopathy and adverse early childhood outcomes
Raymand Pang1, Brian M. Mujuni2, Kathryn A. Martinello1, Emily L. Webb3, Angela Nalwoga2, Julius Ssekyewa2, Margaret Musoke2,
Jennifer J. Kurinczuk4, Margaret Sewegaba2, Frances M. Cowan5, Stephen Cose2,6, Margaret Nakakeeto2, Alison M. Elliott2,6,
Neil J. Sebire7, Nigel Klein7, Nicola J. Robertson1,8 and Cally J. Tann1,2,9
BACKGROUND: Neonatal encephalopathy (NE) contributes substantially to child mortality and disability globally. We compared
cytokine profiles in term Ugandan neonates with and without NE, with and without perinatal infection or inflammation and
identified biomarkers predicting neonatal and early childhood outcomes.
METHODS: In this exploratory biomarker study, serum IL-1α, IL-6, IL-8, IL-10, TNFα, and VEGF (<12 h) were compared between NE
and non-NE infants with and without perinatal infection/inflammation. Neonatal (severity of NE, mortality) and early childhood
(death or neurodevelopmental impairment to 2.5 years) outcomes were assessed. Predictors of outcomes were explored with
multivariable linear and logistic regression and receiver-operating characteristic analyses.
RESULTS: Cytokine assays on 159 NE and 157 non-NE infants were performed; data on early childhood outcomes were available for
150 and 129, respectively. NE infants had higher IL-10 (p < 0.001), higher IL-6 (p < 0.017), and lower VEGF (p < 0.001) levels.
Moderate and severe NE was associated with higher IL-10 levels compared to non-NE infants (p < 0.001). Elevated IL-1α was
associated with perinatal infection/inflammation (p= 0.013). Among NE infants, IL-10 predicted neonatal mortality (p= 0.01) and
adverse early childhood outcome (adjusted OR 2.28, 95% CI 1.35–3.86, p= 0.002).
CONCLUSIONS: Our findings support a potential role for IL-10 as a biomarker for adverse outcomes after neonatal encephalopathy.
Pediatric Research _#####################_ ; https://doi.org/10.1038/s41390-021-01438-1
IMPACT:
● Neonatal encephalopathy is a common cause of child death and disability globally. Inflammatory cytokines are potential
biomarkers of encephalopathy severity and outcome.
● In this Ugandan health facility-based cohort, neonatal encephalopathy was associated with elevated serum IL-10 and IL-6, and
reduced VEGF at birth.
● Elevated serum IL-10 within 12 h after birth predicted severity of neonatal encephalopathy, neonatal mortality, and adverse
early childhood developmental outcomes, independent of perinatal infection or inflammation, and provides evidence to the
contribution of the inflammatory processes.
● Our findings support a role for IL-10 as a biomarker for adverse outcomes after neonatal encephalopathy in a sub-Saharan
African cohort.
INTRODUCTION
Intrapartum-related deaths are the third leading cause of global
neonatal mortality.1 Complications around the time of birth, leading
to neonatal encephalopathy (NE), have been estimated to affect 1.15
million babies globally each year and contribute to many more with
neurodevelopmental impairment (NDI),2 including cerebral palsy
(CP), global developmental delay, vision and hearing impairments,
and seizure disorders.3 NE is defined as a syndrome of impaired
neurological function in the first few hours and days after birth.
Symptoms include reduced consciousness, abnormal tone and
reflexes, seizures, and difficulty maintaining respiration.4 The large
majority (96%) of NE cases occur in low- and middle-income
countries (LMICs), with the greatest burden in sub-Saharan Africa.2 In
resource-limited regions such as sub-Saharan Africa, being able to
identify infants with NE who are at greatest risk of death and
disability could support targeted therapeutic early intervention.
Cytokines and chemokines are potential biomarkers of NE
severity and outcome. Inflammation plays a key role in
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intrapartum-related NE.5,6 An inflammatory cascade in response to
hypoxic–ischemic (HI) injury is well recognized and contributes to
both brain injury and repair.5,6 In addition, preclinical and
observational data suggest that perinatal infection sensitizes
the newborn brain to HI, increasing the risk of NE and
resulting mortality and long-term neurological injury.7–9 Neuroin-
flammation is characterized by microglial activation, cytokine and
chemokine expression, with subsequent infiltration of immune
cells and activation of cell death pathways.5 Cytokines have
the potential to indicate the severity of neuroinflammatory
response following NE and to assist in the detection of
contributing co-infection.
Biomarkers to aid in the accurate prediction, diagnosis and
prognostication for NE are actively sought across high- and low-
resource settings. Validated outcome biomarkers available to
clinicians in sophisticated neonatal intensive care settings, such as
amplitude integrated electroencephalography10, magnetic reso-
nance imaging (MRI) and spectroscopy,11 are not widely available
in LMICs. Practical, cost-effective alternatives are required.
Cytokine profiles in relation to NE have been studied over the
past two decades, with cytokines in serum and cerebrospinal fluid
variably reported to be predictive of neurodevelopmental out-
come after NE.12–15 However, studies to date have been limited by
small numbers, exclusion of infants with evidence of co-infection,
and a lack of long-term outcome data. In addition, studies have
been largely limited to high-resource settings.
We aimed to (1) determine the cytokine profile in term infants
with NE compared to term infants without NE, (2) compare
cytokine profile between NE infants with and without perinatal
infection and inflammation, and (3) identify cytokine biomarkers
for neonatal and early childhood outcomes. We hypothesized that
cytokine levels differ with severity of brain injury and perinatal
infection or inflammation and can therefore play a role in
predicting neonatal and early childhood outcomes.
METHODS
The study was approved by the Uganda Virus Research Institute
Research Ethics Committee, Mulago Hospital Ethics Committee,
London School of Hygiene & Tropical Medicine Research Ethics
Committee, University College London, and the Uganda National
Council for Science and Technology. The reporting of this study
complies with the STROBE (Strengthening The Reporting of
OBservational Studies in Epidemiology) guidelines.
Setting
Uganda is a low-income country with a neonatal mortality rate of
27 per 1000 live births.16 At the time of the study, high-risk
pregnancies were delivered at Mulago National Referral Hospital
(MNRH) in Kampala (study recruitment site). In labor, fetal
monitoring was by intermittent auscultation using a Pinard
stethoscope, assisted deliveries (ventouse/forceps) were not
routinely offered, and one-fifth of deliveries were by cesarean
section (few are electively planned). Midwife-led neonatal
resuscitation included oxygen and bag-mask ventilation. Routine
care in the 70-bed Special Care Baby Unit included continuous
positive airway pressure, intravenous fluids including glucose,
antibiotics and anti-seizure medication, but not mechanical
ventilation, therapeutic hypothermia, cerebral function monitor-
ing, or brain imaging.
Study design and participants
This was an exploratory biomarker study nested within the
ABAaNA (“Abaana,” meaning “children” in the local language
Luganda) study,17 a prospective unmatched case–control study
investigating perinatal risk factors for NE among neonates born at
MNRH between September 2011 and October 2012, followed by a
cohort comparison study of recruited infants followed up to 2
years of age. The research methodology and primary results have
been described previously.17–20 In summary, term infants
(≥37 weeks gestation) with NE (Thompson score21 ≥6 within 12
h of birth) and an unmatched comparison group of term infants
without NE were included. Control infants were contempora-
neously recruited (at a case:control ratio of 1:2), systematically
sampled from the labor ward admission book, and were eligible if
their Thompson score was <3 (as assessed by trained MNRH study
physicians). Exclusion criteria for both NE and non-NE infants
included living >20 km from MNRH, being out-born, neonatal
antibiotic administration prior to recruitment (rare), and no written
informed parental consent.
Serum cytokine specimen collection and processing
At the time of recruitment, 0.5 ml of serum for cytokine analysis
was obtained from all infants and stored at −80 °C. Cytokine
samples were processed for all infants with NE. For the
comparison group, a subset of serum cytokine samples was
selected at random using a table generated in Stata v11.2® (with
one comparison group sample selected for every infant with NE)
and processed. Samples were thawed and processed using
multiplex cytokine immunoassay (Luminex) between 13 and 17
May 2014, during the neurodevelopmental follow-up phase of the
study. Samples with <0.5 ml volume and any incorrectly labeled
were excluded. Serum concentrations of interleukin (IL)-1 alpha
(IL-1α), IL-6, IL-8, IL-10, tumor necrosis factor alpha (TNFα), and
vascular endothelial growth factor (VEGF) were measured using
Human premixed multi-analyte kits (R&D Systems, Minneapolis,
USA) on the Bio Plex200 platform (Bio Plex™, Bio Rad Laboratories).
Cytokine concentrations were obtained from the Bio Plex manager
software. Cytokine concentrations below the detection limit were
assigned zero and values above the detection limit were assigned
the value of the highest concentration standard.
Perinatal infection and inflammation
At recruitment, blood samples were obtained for blood culture,
species-specific bacterial detection using quantitative polymerase
chain reaction (qPCR), and c-reactive protein (CRP) measurement
from all infants with NE and from control infants with a clinical
suspicion of sepsis as previously published.19 Isolated colonies
from blood culture were manually identified. Multiplex real-time
qPCR assays for pathogenic bacteria among newborns (group B
Streptococcus, Pneumococcus, Staphylococcus aureus, group A
streptococcus, Enterobacteriaceae sp.) were performed.13,15 Neo-
natal bacteremia was defined as either positive isolated colonies
on blood culture or positive detection from qPCR assay. Maternal
and neonatal CRP were measured as a marker of inflammation
and are presented according to centiles among control mothers
and infants, respectively, consistent with the reporting of the main
study findings.13
The examination of placental histology was not routine at
MNRH. In the ABAaNA study, placental histology was reported in
around a quarter of NE (60/210) and non-NE (102/409) infants.13
Whole placentas were collected and fixed in 10% formalin and
specimens were processed according to standard protocols.13
Histology was reported by an experienced perinatal pathologist
based at the Camelia Botnar Laboratories, Great Ormond Street
Hospital, UK, blinded to all clinical details. Histological chorioam-
nionitis and funisitis were diagnosed according to standard
criteria.22
Neonatal outcomes
Severity of encephalopathy was graded (mild, moderate, or
severe) daily between days 1 and 5 according to the modified
Sarnat classification23 and the grading used was the most severe
recorded. The Sarnat score was determined by the principal
investigator based on the clinical variables collected. Neonatal
death was defined as death in the first 28 days after birth.
Elevated serum IL-10 is associated with severity of neonatal. . .




The procedure used in the current study for neurodevelopmental
follow-up has been previously reported.18 In summary, children
were assessed at 12–15 and 27–30 months of age, either in
outpatient clinic or at home (<5%). Transport costs were
remunerated. Further informed written consent was taken at
these visits. In case of death, parental report of causation and date
of death was obtained.
Neurodevelopmental assessment was performed by trained and
certified assessors, blinded to the presence of NE, clinical history,
and investigations. Griffith’s Mental Developmental Scales-II
(GMDS) was used to calculate a global Development Quotient
(DQ) from the six subscales (A–F). The Hammersmith Infant
Neurological Examination (HINE) (https://hammersmith-neuro-
exam.com) provided a standardized score, which has been
validated as a predictor of motor outcome at 12–18 months but
is frequently extended into use in the second year.24,25 CP was
diagnosed according to the Surveillance of Cerebral Palsy in
Europe classification26 as spastic bilateral, spastic unilateral,
dyskinetic, dystonic, choreo-athetotic, ataxic, or non-classifiable.
Videos for children with a suboptimal HINE score (<73) or any
asymmetries were reviewed by a minimum of two blinded
investigators with expertise in NDI and consensus was reached in
all cases. NDI was defined as a global DQ < 70 on GMDS and/or
HINE score <67 and/or diagnosis of CP.
Statistical analysis
Statistical analysis was carried out using SPSSv24 (IBM) and Prism
v8 (GraphPad, USA). Data were assessed for normality and, where
necessary, log10 transformed to normalize the distribution. Where
relevant, data were back transformed and presented as geometric
mean ratios.
Characteristics of participants with and without cytokine data
were compared using chi-squared and t tests. Crude comparisons
of serum cytokine concentrations between non-NE infants and NE
infants were initially done using Mann–Whitney U tests due to the
non-normal distribution of some cytokines. A multivariable linear
regression model was fitted for each log10 transformed cytokine,
adjusting for time of sampling and infant sex to identify significant
differences in the cytokine profiles between the groups after
adjusting for these potential confounders. The multivariable linear
regression model was also used to identify significant differences
between NE infants with and without perinatal infection or
inflammation, adjusted for infant sex and time of sampling.
Neonatal CRP >97th centile, bacteremia, maternal CRP >90th
centile and histological funisitis, previously identified as risk
factors for NE in our parent study,17 were utilized in this study to
define perinatal infection/inflammation.
For neonatal outcomes, cytokine levels for NE infants by the
highest modified Sarnat score in the first 5 days were compared
with those of non-NE infants using Kruskal–Wallis with post hoc
Dunn–Bonferroni tests. The crude levels were also compared
between NE infants who survived and those who died and a
multivariable logistic regression analysis was carried out among
infants with NE to assess the ability of cytokine levels to predict
neonatal fatality, adjusting for time of sampling and infant sex.
For early childhood outcomes, adverse outcome was defined as
death or NDI. Where possible, 2-year neurodevelopmental out-
comes were used; however, where absent, 1-year outcome data
were included to minimize bias. A random sample of non-NE
infants with both 1- and 2-year outcome data were compared to
ensure consistency between the two follow-up time points. Crude
serum cytokine concentrations were compared between non-NE
infants, NE infants with favorable outcomes, and NE infants with
adverse outcomes using Kruskal–Wallis with post hoc
Dunn–Bonferroni tests. A multivariable logistic regression model
was fitted to identify the ability of cytokines to predict adverse
early childhood outcomes among children with NE, adjusting for
infant sex, time of sampling, and neonatal bacteremia. Receiver-
operator characteristic curves were constructed to determine the
predictive value of cytokines.
Sample size
The sample size for this substudy was determined by the
availability of serum samples from the original ABAaNA study.
We carried out a post hoc power calculation based on the
calculated standard deviations for each of the cytokine concen-
tration values on the log10 scale in our dataset, which ranged from
1.02 to 2.88. Therefore, for the first objective of determining the
cytokine profile in infants with NE compared with that of the
comparison group of term infants without NE, we had 80% power
to detect an absolute difference in mean log cytokine levels
between NE and non-NE infants ranging from 0.32 to 0.90, at 5%
significance level, for the various cytokines.
RESULTS
During the 13-month recruitment period (September 2011 to
October 2012), 36,926 infants were born at MNRH, from whom 210
with NE and 409 without NE were recruited to the original (parent)
ABAaNA study. Serum samples, taken on recruitment, were
processed for all NE participants with available stored serum
samples (n= 159) and a random sample of 157 non-NE
participants who act as a control group for this biomarker sub-
study. The flow of participants through this nested substudy is
summarized in Fig. 1. No differences were seen in baseline
characteristic between those from the parent study who did and
did not have cytokine data.
In the parent study, neurodevelopmental follow-up at 2 years
were undertaken for infants without NE, selected at a ratio of two
non-NE infants to one surviving NE child, resulting in 53 control
infants deliberately excluded. Sixteen infants with cytokine data
fell within this group and were not included in analyses relating
cytokines to later outcomes.
Cytokine profile in NE infants compared to controls
Blood samples for cytokine concentrations were taken at a mean
age of 3.4 h (SD 2.44 h) in the NE cohort and 6.7 h (SD 2.19 h) in
infants without NE (p < 0.001). Crude analysis of the cytokine
profile demonstrated significant differences in TNFα, VEGF, and
IL-10 levels between the NE and non-NE infants (Table 1).
Following linear regression analysis, adjusting for time of
cytokine blood sampling and infant sex, VEGF, IL-6, and IL-10
remained significantly different between groups (Table 1).
NE was associated with elevated serum IL-6 (p= 0.017) and
IL-10 (p < 0.001) levels compared to non-NE infants (Table 1). In
contrast, VEGF was lower in infants with NE compared to non-NE
infants (p < 0.001). In crude analysis, higher TNF levels were
observed in NE infants (p= 0.001) compared to non-NE infants;
however, significance was lost following adjusting for variables
with linear regression.
Cytokine profile in NE infants with perinatal inflammation/
infection risk factors
We compared cytokine levels among NE infants with and without
evidence of perinatal infection/inflammation and observed higher
levels of IL-1α in NE infants (p= 0.013) with exposure to
histological funisitis compared to NE infants without exposure
(Table 2). No differences in the remaining cytokine levels were
observed among NE infants with and without indicators of
perinatal inflammation/infection (Table 2).
Neonatal outcomes
Severity of encephalopathy. Encephalopathy grades were: 15 mild
(9.4%), 87 moderate (54.7%), and 57 severe (35.8%), based on the
highest modified Sarnat score over the first 5 days after birth.
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Table 1. Associations between cytokine levels and neonatal encephalopathy.
Cytokine NE (n= 159), median (IQR) Non-NE (n= 157), median (IQR) p valuea Adjusted geometric mean ratio (95% CI)b p value
TNFα 5.24 (2.49–10.0) 7.76 (4.15–15.0) 0.001 0.81 (0.64, 1.04) 0.093
IL-8 260 (46.9–1138) 285 (30.0–1179) 0.910 0.97 (0.48, 1.95) 0.931
VEGF 91.6 (16.6–201) 203 (82.1–367) <0.001 0.33 (0.22, 0.49) <0.001
IL-1α 2.33 (0.05–5.49) 3.22 (0.05–7.90) 0.204 0.79 (0.57, 1.08) 0.142
IL-6 24.6 (8.43–81.1) 18.5 (7.19–52.1) 0.096 1.69 (1.10, 2.58) 0.017
IL-10 6.72 (0.58–24.5) 0.97 (0–3.17) <0.001 2.93 (2.07, 4.15) <0.001
Data shown are median serum cytokine levels in pg/ml (interquartile range).
Bold values indicate statistical significance p < 0.05.
NE neonatal encephalopathy, TNFα tumor necrosis factor alpha, IL interleukin, VEGF vascular endothelial growth factor.
aMann–Whitney U test.
bLinear regression analysis with geometric mean difference in cytokine levels (pg/ml) and 95% confidence intervals (95% CIs) between NE and non-NE infants,
adjusted for neonatal sex and time of cytokine blood sample.











p value Adjusted geometric mean
ratio (95% CI)
p value Adjusted geometric mean
ratio (95% CI)
p value Adjusted geometric mean
ratio (95% CI)
p value
TNFα 0.98 (0.55, 1.77) 0.951 1.27 (0.68, 2.37) 0.446 1.79 (0.85, 3.81) 0.125 1.10 (0.77, 1.57) 0.597
IL-8 0.96 (0.18, 5.00) 0.959 0.89 (0.15, 5.15) 0.895 1.81 (0.32, 10.28) 0.493 0.54 (0.20, 1.47) 0.223
VEGF 0.58 (0.20, 1.71) 0.325 2.19 (0.70, 6.82) 0.176 1.35 (0.38, 4.78) 0.632 1.23 (0.63, 2.40) 0.540
IL-1α 1.63 (0.80, 3.31) 0.180 1.00 (0.47, 2.14) 0.999 2.88 (1.27, 6.58) 0.013 1.19 (0.77, 1.83) 0.435
IL-6 0.58 (0.20, 1.67) 0.308 1.36 (0.44, 4.24) 0.591 2.54 (0.82, 7.87) 0.103 0.68 (0.35, 1.31) 0.249
IL-10 0.67 (0.26, 1.72) 0.399 0.89 (0.33, 2.44) 0.824 0.78 (0.20, 3.07) 0.719 0.99 (0.55, 1.78) 0.961
Multivariable linear regression analysis; differences are shown as the geometric mean ratio in cytokine levels (pg/ml) with 95% confidence intervals (95% CIs),
adjusted for infant sex and time of cytokine blood sampling.
Bold values indicate statistical significance p < 0.05.
aN denotes the number of positive results out of the total numbers of test results available. Within this nested cohort of NE infants with cytokine data, blood
culture and qPCR data were available for all infants (n= 159), neonatal CRP was available for 158 infants, placental histology data were available for 45 NE
cases, and maternal CRP data were available in 156 NE cases.
bDefined as neonatal CRP > 97th centile among ABAaNA study non-NE infants (CRP > 31.7 mg/l).





Cytokine samples selected at random to


















Death (neonatal 1, postnatal 2)
No impairment 122
Serum sample not processed (252)
Lost to follow-up (16)
Relocated (6)
Excluded - too old at follow-up (4)
Excluded from original ABAaNA study as
recruitment numbers met (15)
Withdrew from study (12)
Lost to follow-up (8)
Excluded - too old at follow-up (2)
Withdrew from study (2)
Mild impairment 3
Moderate-severe impairment 2
Death (neonatal 1, postnatal 1)
Lost to follow-up (5)
1 year outcome (n=155)
2 year outcome (n=150) 2 year outcome (n=92)
1 year outcome (n=129)
Fig. 1 Study Participants. Flow diagram of participants and neurodevelopmental outcomes.
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Median cytokine levels of non-NE infants and by severity of
encephalopathy for NE infants are shown in Fig. 2. IL-10 serum
levels were higher in both moderate and severely encephalo-
pathic infants compared to the non-NE cohort (p < 0.001). We also
observed a trend with severity; IL-10 levels were higher in infants
with moderate (p= 0.046) and severe (p= 0.009) encephalopathy
compared to infants with mild encephalopathy. We observed
lower VEGF serum concentrations in infants with moderate (p <
0.001) and severe encephalopathy (p < 0.001) compared with non-
NE infants. No difference in VEGF levels were observed between
the NE severity groups. Serum TNFα, IL-8, IL-1α, and IL-6 did not
differ between the groups.
Neonatal fatality. Fifty-two (32.7%) infants with NE died in the
first 28 postnatal days compared to 1 (0.6%) infant in the non-NE
group. Crude serum cytokine levels for infants with NE who
survived compared to those who died in the first 28 days are
shown in Fig. 2b. After adjustment for time of cytokine blood
sampling and infant sex using a multivariable logistic regression
model, IL-10 levels doubled the odds of neonatal fatality (adjusted
odds ratio (aOR) 2.02, 95% confidence interval (CI) 1.22–3.38, p=
0.007). All other cytokine levels were not discriminatory in
predicting mortality.
Early childhood outcomes
Two-year neurodevelopmental outcome data were available for
150 NE infants and 92 non-NE infants. In addition, 1-year
(12–15 months) outcome data were available for a further 37
non-NE infants. To ensure consistency between the 1- and 2-year
outcome data, a random sample of 37 non-NE infants with both 1-
and 2-year outcome data available were assessed. Data between
the two time points correlated; all non-NE infants had favorable
neurodevelopmental outcomes in both 1- and 2-year data.
Therefore, where 2-year data were not available, 1-year outcome
data were used and early childhood outcome data in the non-NE
group totaled 129 infants.
Adverse early childhood outcomes, defined as moderate to
severe impairment or death, occurred in 89 of the 150 (59.3%)
infants with NE and 4 of the 129 (3.1%) infants without NE.
Cytokine profiles for non-NE infants and NE infants with favorable
or adverse outcomes are shown in Fig. 3. NE infants with adverse








































































































































Mild NE Moderate NE Severe NE Non-NE Mild NE Moderate NE Severe NE Non-NE Mild Moderate Severe
Non-NE Mild Moderate SevereNon-NE Mild Moderate SevereNon-NE Mild Moderate Severe
Fig. 2 Cytokine profiles and neonatal outcomes. a Comparison of cytokine levels (pg/ml) between non-NE infants and NE infants by severity
of NE (according to the highest modified Sarnat score in the first 5 days of life). b Comparison of cytokine levels (pg/ml) between infants with
NE who survived or died in the first 28 days of life. Box plots showing the median, interquartile range, and range of the data. Differences
between groups were compared using Kruskal–Wallis test *p < 0.05, **p < 0.01, and ***p < 0.001.
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favorable outcomes (p= 0.005) who in turn had higher levels of IL-
10 than infants without NE (p= 0.04). On multivariable logistic
regression analysis, IL-10 was a predictor of adverse early
childhood outcomes (aOR 2.28, 95% CI 1.35–3.86, p= 0.002;
Table 3). We also observed lower VEGF levels in both NE groups
when compared to infants without NE and higher TNFα levels in
NE infants with favorable outcome compared to non-NE infants
(Fig. 3); however, these were not strongly discriminatory in
predicting 2-year adverse outcomes in the adjusted analysis (p=
0.05; Table 3).
Outcomes in infants with NE are shown in Fig. 4. IL-10
demonstrated an area under the curve (AUC) value of 0.646
(95% CI 0.555–0.736, p= 0.003). Using a cut-off log10 IL-10 value of
0.225, for a prevalence of 59.3% of adverse outcome, the
sensitivity and specificity were 88.8 and 36.1%, respectively, with
a positive predictive value of 66.9% and negative predictive value
of 82.4%. All other cytokine values had AUC values close to 0.5
with corresponding p > 0.05.
DISCUSSION
We report selected inflammatory cytokine profiles in the first 12 h
after birth in a large cohort of babies with and without NE from a
sub-Saharan African hospital setting in Kampala, Uganda. We
observed that serum concentrations of IL-10, IL-6, and VEGF were
associated with a clinical diagnosis of NE and that serum IL-10
levels within a mean of 3.4 h after birth were higher in
moderate–severe NE (based on the worst daily modified Sarnat
score) compared to mild NE and no NE. Elevated serum IL-10
levels predicted neonatal mortality (<28 days after birth) and
adverse early neurodevelopmental outcomes at 2 years, indepen-
dent of evidence for perinatal infection/inflammation. Using a cut-
off of 0.225 for serum log10 (IL-10), the sensitivity and specificity
for predicting adverse early childhood outcomes (mortality or NDI)
at 2 years was 88.8 and 36.1%, respectively.
NE was associated with elevated IL-6 and IL-10 and reduction in
VEGF levels compared to non-NE infants. Cytokines are released
















































































































































Fig. 3 Cytokine profiles and early childhood outcomes. Cytokine levels (pg/ml) in non-NE infants, NE infants with favorable outcomes, and
NE infants with adverse outcomes. Adverse outcomes defined as death or neurodevelopmental impairment (global DQ < 70 on GMDS and/or
HINE score <67 and/or diagnosis of CP at 1–2 years). Box plots showing the median, interquartile range, and range of the data. Differences
between groups were compared using Kruskal–Wallis test where *p < 0.05, **p < 0.01, and ***p < 0.001.
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response to hypoxia–ischemia, modulating the inflammatory
response to brain injury.27 Past studies of cytokine profiles in NE
infants have reported variable, often conflicting, results but have
been limited by small sample sizes. A recent small case–control
study identified a panel of 17 out of 40 measured cytokines and
chemokines, including IL-10, which were elevated within the first
6 h of life in infants with NE compared with healthy term
controls.28 However, that study did not find an association
between NE and IL-6 or VEGF. By contrast a number of
observational studies have demonstrated elevated serum IL-6 in
infants with NE in the first days after birth compared to non-NE
infants.29–34 Serum VEGF has previously been demonstrated to be
lower in infants with NE compared with controls from serial blood
samples taken over the first 24 h after birth.35
We have previously reported perinatal infection and inflamma-
tion as independent risk factors for NE in this Ugandan
population.17 Biomarkers to detect NE infants with contributing
perinatal infection are sought in order identify infants at greater
risk of poor outcome and, in the future, to tailor therapy. In this
study, we observed IL-1α levels were higher in NE infants exposed
to histological funisitis compared to NE infants without such
exposure. IL-1α is a potent pro-inflammatory cytokine. Levels of IL-
1 are elevated in amniotic fluid of women with chorioamnionitis36
and have been directly implicated in the fetal inflammatory
response.37,38 Despite the association with funisitis, serum IL-1α
was not predictive of short- or long-term outcome after NE in our
cohort. It is possible that the association between IL-1α and
funisitis is a chance finding due to multiplicity. No other measured
serum cytokines were able to discriminate infection or inflamma-
tion exposure among infants with NE.
We observed that IL-10 levels was elevated in moderate and
severe NE, compared to mild NE and non-NE infants, and
associated with adverse early childhood outcomes. The associa-
tions between raised IL-10 and NE severity,39 neonatal mortal-
ity,40,41 and early childhood NDI in NE42 have been reported
previously in several smaller studies. IL-10 is an anti-inflammatory
cytokine released via a Toll-like receptor 2/nuclear factor-κB-
dependent pathway43,44 following HI.45 Whether elevated IL-10
reflects, or contributes to, severity of brain injury is unclear.
Traditionally, pro-inflammatory responses have been implicated in
neuronal injury and anti-inflammatory cytokines associated with
inflammation resolution, neuronal survival, and repair.5 Paradoxi-
cally, there is preclinical evidence that IL-10 may exacerbate brain
injury.46 Clinically, IL-10 has also been implicated in immunopar-
alysis, a term to describe the pathologically blunted inflammatory
response resulting from a persistence of marked compensatory
anti-inflammatory signaling.47 An association between
Table 3. Multivariable logistic regression analysis of cytokines to
predict adverse early childhood outcomes among infants with NE.
Unadjusted OR
(95% CI)
p value Adjusted ORa
(95% CI)
p value
TNFα 2.18 (1.01, 4.68) 0.047 2.25 (1.00, 5.07) 0.050
IL-8 0.913 (0.71, 1.18) 0.489 0.933 (0.71, 1.22) 0.610
VEGF 0.726 (0.48, 1.10) 0.127 0.748 (0.49, 1.15) 0.185
IL-1α 0.971 (0.53, 1.78) 0.923 1.05 (0.56, 1.96) 0.888
IL-6 1.26 (0.83, 1.92) 0.276 1.17 (0.76, 1.81) 0.475
IL-10 2.11 (1.28, 3.48) 0.003 2.28 (1.35, 3.86) 0.002
Adverse outcome was defined as death or neurodevelopmental impair-
ment (global DQ < 70 on GMDS and/or HINE score <67 and/or diagnosis of
CP at 1–2 years). Results show the OR for adverse outcome per unit
increase in log10 (cytokine levels).
Bold values indicate statistical significance p < 0.05.
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Fig. 4 Predictive value of cytokines for early childhood outcomes in NE. ROC curve analysis of cytokine profiles in infants with NE to predict
adverse early childhood outcomes.
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immunoparalysis and adverse outcomes has been observed in the
pediatric intensive care setting following cardiopulmonary
bypass,46 sepsis, and trauma.48 In cooled infants with NE,
chemokine-mediated leukopenic immunoparalysis was observed
in infants with poor outcome at 12 months (death or NDI).49 In
vitro studies report the inhibition of pro-inflammatory TNFα
production by IL-10.50,51 In our study, we observed that TNFα was
not elevated among infants with NE, even in association with
perinatal infection and inflammation. The balance between a pro-
inflammatory and anti-inflammatory phenotype is complex and
likely key to neurogenesis and repair following neonatal brain
injury during the period of tertiary brain injury.52,53 Importantly,
altered inflammatory response in the neonatal period may have
longer-term implications. Recently, Zareen et al. showed altered
cytokine response persisting into school age after NE; IL-10 levels
remained elevated in infants with NE and hyporesponsiveness to
lipopolysaccharide stimulation was observed in several cytokines,
including IL-10.54 Neuroprotective interventions targeted at
modulating the inflammatory response may further improve
outcomes in infants with NE. In preclinical studies, mesenchymal
stem cell therapy administered to rats subjected to HI injury was
associated with a reduction in IL-10 levels, reduction in brain cell
death, and improved learning memory function.55
Adverse neurodevelopmental outcome after NE was common
in this population, affecting nearly one-third of NE survivors.18
Neuroprotective interventions available for infants with NE in low-
income settings are limited. The benefits of therapeutic hypother-
mia remains uncertain in this setting.56,57 Animal studies suggest
that cooling may not be neuroprotective in combination with
infection and inflammation,58 whereas clinical studies showed
more variable findings.59,60 A large multi-center randomized
controlled trial in LMICs is currently underway, but these results
may not be generalizable to sub-Saharan Africa.61 Identifying
biomarkers to risk stratify for early intervention and future
neuroprotective trials are urgently needed. Here we demonstrated
that IL-10 can predict adverse neurodevelopmental outcome with
a reasonable sensitivity of 88.8% and negative predictive value of
82.4% using a log10 IL-10 threshold value of 0.225. We opted for a
cut-off value that maximizes the identification of at-risk infants
and reduces false negative results as it is important in this setting
that we avoid missing infants who may benefit the most from
early interventional programs62 and future neuroprotective
therapies. Inflammatory cytokines have been explored as potential
biomarkers for NE; however, their predictive accuracy has varied
across different studies.12 The temporal evolution of cytokines
after HI injury35,42,63 may in part explain this variability. In a study
of cytokines nested within a randomized control trial investigating
erythropoietin as an adjunct agent with therapeutic hypothermia
for NE, IL-10 at 16.2 h showed a modest correlation with global
brain injury score on MRI; however, no correlation was observed
when IL-10 was measured on day 5.13 In the piglet model of HI,
Rocha-Ferreira et al.64 showed that serum IL-10 levels peaked at
36 h after HI followed by a gradual decline. IL-10 correlated with
magnetic resonance spectroscopy-measured lactate/N-acetyl
aspartate peak ratio, a robust biomarker of outcomes in infants
with NE.11 A biphasic response in IL-6 exists as seen in both
clinical42 and preclinical studies,64 with a secondary rise at 36–48
h, which may explain the poor correlation in IL-6 with outcomes
observed in this study. Similarly, VEGF levels evolves in the first
four days of life and its correlation with NE severity varies
according to time of cytokine measurement.65 Serial measurement
of cytokine may further improve accuracy to predict outcomes
and therefore requires further investigation.
The study has several limitations. Cytokine data were only
available for a single time point. Serial cytokine data correlated
with outcomes may provide further insight into the evolution of the
neuroinflammatory profile of babies with NE and the optimal timing
of measurement to provide the best predictive value as a biomarker.
Placental histology was examined in only a quarter of cases, leading
to potential under-representation of chorioamnionitis in this cohort,
which may be a confounding factor in cytokine expression.
Histological chorioamnionitis was used rather than clinical chor-
ioamnionitis as histology more reliably predict intrauterine inflam-
mation.66,67 Although infants who received antibiotics prior to
enrollment were excluded from the parent study, this was
uncommon and unlikely to have introduced bias. While the
diagnosis of neonatal bacteremia was strengthened by using
species-specific bacterial PCR in addition to blood cultures, under-
diagnosis cannot be excluded. Although assessment of a random
sample of infants showed a good correlation between 1- and 2-year
outcomes, later childhood outcomes at school age would enable
exploration of associations with longer-term outcomes.
CONCLUSION
Inflammatory cytokines may induce, modify, and indicate NE
severity and outcome. In this cytokine substudy nested within the
ABAaNA study,17 a prospective unmatched case–control study
investigating perinatal risk factors for NE in Uganda, serum IL-10
levels at 3 h were significantly elevated in infants with NE and
predicted neonatal mortality and adverse neurodevelopmental
outcomes at 2 years. IL-10 is an anti-inflammatory cytokine and
may have a role in modulating brain injury long term through the
nature of the pro-inflammatory response to HI. Serum IL-10 shows
promise as a biomarker to predict adverse early childhood
outcomes and may be useful in future neuroprotection trials
targeted to infants at the highest risk of death or NDI.
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